Author

P. Rischmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. De Reynies· 1 shared A. Kamoun· 1 shared C. Beraud· 1 shared C. Krucker· 1 shared C. S. Groeneveld· 1 shared E. Chapeaublanc· 1 shared F. Dufour· 1 shared F. Radvanyi· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. De Reynies

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

H. Lang, C. Beraud, L. Cabel, M. Lassalle, J. Fontugne, C. Krucker, F. Dufour, C. S. Groeneveld, V. Dixon, X. Meng, A. Kamoun, E. Chapeaublanc, A. De Reynies, X. Game, P. Rischmann, , T. Massfelder

The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.

Frontiers in Oncology · Aug 11, 2022Peer-reviewedCancer Biology